A Trial of Napabucasin (BBI-608) Plus Weekly Nab-paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

**Key Inclusion Criteria**
- Age ≥18 years
- ECOG PS 0 or 1
- Life expectancy >12 weeks
- Histologically or cytologically confirmed metastatic PDAC
- Not received chemotherapy or any investigational agent for the treatment of PDAC
- Nab-paclitaxel with gemcitabine therapy is appropriate for the patient and recommended by the Investigator

**Study Locations**
Global sites in Asia, North America, and Europe, including Japan and the US, are actively recruiting. Please check www.clinicaltrials.gov for updates about this study (NCT02993731) and for a listing of clinical study site locations.

**About Napabucasin**
Napabucasin is an investigational, orally administered agent hypothesized to inhibit cancer stemness pathways, and has not yet been approved by the FDA or any other health authorities.

**Primary Endpoint**
- Overall survival (OS)

**Secondary Endpoints**
- OS in biomarker-positive* patients
- Progression-free survival (PFS)
- PFS in biomarker-positive* patients
- Overall response rate (ORR) and disease control rate (DCR)
- ORR and DCR in biomarker-positive* patients
- Quality of life
- Safety

*Defined as those patients with phospho-STAT3 positivity on immunohistochemical staining of formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
PHASE III

A Trial of Napabucasin (BBI-608) Plus Weekly Nab-paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Boston Biomedical, Inc. is a leading developer of next-generation cancer therapeutics designed to inhibit cancer stemness pathways and modify immune responses.